Fan Fiction

ASH CAP Initial Workup of Acute Leukemia Included References for Data Extraction

ASH CAP Initial Workup of Acute Leukemia Included References for Data Extraction 1. Busse, N. Gokbuget, J. M. Siehl, D. Hoelzer, S. Schwartz, A. Rietz, E. Thiel and U. Keilholz. Wilms' tumor gene 1 (WT1)
of 20
All materials on our website are shared by users. If you have any questions about copyright issues, please report us to resolve them. We are always happy to assist you.
Related Documents
ASH CAP Initial Workup of Acute Leukemia Included References for Data Extraction 1. Busse, N. Gokbuget, J. M. Siehl, D. Hoelzer, S. Schwartz, A. Rietz, E. Thiel and U. Keilholz. Wilms' tumor gene 1 (WT1) expression in subtypes of acute lymphoblastic leukemia (ALL) of adults and impact on clinical outcome. Annals of Hematology : Dufour, F. Schneider, K. H. Metzeler, E. Hoster, S. Schneider, E. Zellmeier, T. Benthaus, M. C. Sauerland, W. E. Berdel, T. Buchner, B. Wormann, J. Braess, W. Hiddemann, S. K. Bohlander and K. Spiekermann. Acute myeloid leukemia with biallelic CEBPA gene mutations and normal karyotype represents a distinct genetic entity associated with a favorable clinical outcome. J Clin Oncol : J. Mead, D. C. Linch, R. K. Hills, K. Wheatley, A. K. Burnett and R. E. Gale. FLT3 tyrosine kinase domain mutations are biologically distinct from and have a significantly more favorable prognosis than FLT3 internal tandem duplications in patients with acute myeloid leukemia. Blood : Jaworska-Posadzy, J. Styczynski, M. Kubicka, R. Debski, B. Rafinska-Kurylo, B. Kolodziej, M. Pogorzala and M. Wysocki. Prognostic value of persistent peripheral blood and bone marrow lymphoblasts on day 15 of therapy in childhood acute lymphoblastic leukemia as detected by flow cytometry. Anticancer Research : Kuhnl, N. Gokbuget, A. Stroux, T. Burmeister, M. Neumann, S. Heesch, T. Haferlach, D. Hoelzer, W. K. Hofmann, E. Thiel and C. D. Baldus. High BAALC expression predicts chemoresistance in adult B-precursor acute lymphoblastic leukemia. Blood : Neubauer, K. Maharry, K. Mrozek, C. Thiede, G. Marcucci, P. Paschka, R. J. Mayer, R. A. Larson, E. T. Liu and C. D. Bloomfield. Patients with acute myeloid leukemia and RAS mutations benefit most from postremission high-dose cytarabine: a Cancer and Leukemia Group B study. J Clin Oncol : Ongaro, M. De Mattei, M. G. Della Porta, G. Rigolin, C. Ambrosio, F. Di Raimondo, A. Pellati, F. F. Masieri, A. Caruso, L. Catozzi and D. Gemmati. Gene polymorphisms in folate metabolizing enzymes in adult acute lymphoblastic leukemia: effects on methotrexaterelated toxicity and survival. Haematologica : Pulsoni, S. Iacobelli, M. Bernardi, M. Borgia, A. Camera, N. Cantore, F. Di Raimondo, P. Fazi, F. Ferrara, F. Leoni, V. Liso, M. Mancini, F. Marmont, A. Matturro, L. Maurillo, L. Melillo, G. Meloni, S. Mirto, G. Specchia, C. G. Valentini, A. Venditti, G. Leone, R. Foa, F. Mandelli and L. Pagano. M4 acute myeloid leukemia: the role of eosinophilia and cytogenetics in treatment response and survival. The GIMEMA experience. Haematologica : R. Chauvenet, P. L. Martin, M. Devidas, S. B. Linda, B. A. Bell, J. Kurtzberg, J. Pullen, M. J. Pettenati, A. J. Carroll, J. J. Shuster and B. Camitta. Antimetabolite therapy for lesser-risk B- lineage acute lymphoblastic leukemia of childhood: a report from Children's Oncology Group Study P9201. Blood : Renneville, N. Boissel, N. Gachard, D. Naguib, C. Bastard, S. de Botton, O. Nibourel, C. Pautas, O. Reman, X. Thomas, C. Gardin, C. Terre, S. Castaigne, C. Preudhomme and H. Dombret. The favorable impact of CEBPA mutations in patients with acute myeloid leukemia is only observed in the absence of associated cytogenetic abnormalities and FLT3 internal duplication. Blood : Renneville, N. Boissel, O. Nibourel, C. Berthon, N. Helevaut, C. Gardin, J. M. Cayuela, S. Hayette, O. Reman, N. Contentin, D. Bordessoule, C. Pautas, S. d. Botton, T. d. Revel, C. Terre, P. Fenaux, X. Thomas, S. Castaigne, H. Dombret and C. Preudhomme. Prognostic significance of DNA methyltransferase 3A mutations in cytogenetically normal acute myeloid leukemia: a study by the Acute Leukemia French Association. Leukemia : Shimada, T. Taki, K. Tabuchi, T. Taketani, R. Hanada, A. Tawa, M. Tsuchida, K. Horibe, I. Tsukimoto and Y. Hayashi. Tandem duplications of MLL and FLT3 are correlated with poor prognoses in pediatric acute myeloid leukemia: a study of the Japanese childhood AML Cooperative Study Group. Pediatric Blood & Cancer : Troeger, L. Glouchkova, B. Ackermann, G. Escherich, R. Meisel, H. Hanenberg, M. L. den Boer, R. Pieters, G. E. Janka-Schaub, U. Goebel, H. J. Laws and D. Dilloo. High expression of CD40 on B-cell precursor acute lymphoblastic leukemia blasts is an independent risk factor associated with improved survival and enhanced capacity to up-regulate the death receptor CD95. Blood : Troeger, S. Gudowius, G. Escherich, M. L. den Boer, L. Glouchkova, B. Ackermann, R. Meisel, H. J. Laws, M. Groeger, R. Wessalowski, R. Willers, J. Harbott, R. Pieters, U. Goebel, G. E. Janka-Schaub, H. Hanenberg and D. Dilloo. High nerve growth factor receptor (p75ntr) expression is a favourable prognostic factor in paediatric B cell precursor-acute lymphoblastic leukaemia. Br J Haematol : V. Moorman, C. J. Harrison, G. A. Buck, S. M. Richards, L. M. Secker-Walker, M. Martineau, G. H. Vance, A. M. Cherry, R. R. Higgins, A. K. Fielding, L. Foroni, E. Paietta, M. S. Tallman, M. R. Litzow, P. H. Wiernik, J. M. Rowe, A. H. Goldstone and G. W. Dewald. Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial. Blood : V. Moorman, C. Schwab, H. M. Ensor, L. J. Russell, H. Morrison, L. Jones, D. Masic, B. Patel, J. M. Rowe, M. Tallman, A. H. Goldstone, A. K. Fielding and C. J. Harrison. translocations, CRLF2 deregulation, and microdeletions in adolescents and adults with acute lymphoblastic leukemia. Journal of Clinical Oncology : V. Moorman, H. M. Ensor, S. M. Richards, L. Chilton, C. Schwab, S. E. Kinsey, A. Vora, C. D. Mitchell and C. J. Harrison. Prognostic effect of chromosomal abnormalities in childhood B- cell precursor acute lymphoblastic leukaemia: results from the UK Medical Research Council ALL97/99 randomised trial. Lancet Oncol : V. Moorman, S. M. Richards, H. M. Robinson, J. C. Strefford, B. E. S. Gibson, S. E. Kinsey, T. O. B. Eden, A. J. Vora, C. D. Mitchell, C. J. Harrison and U. K. M. R. C. N. C. R. I. C. L. W. Party. Prognosis of children with acute lymphoblastic leukemia (ALL) and intrachromosomal amplification of chromosome 21 (iamp21). Blood : Vitale, A. Guarini, C. Ariola, G. Meloni, O. Perbellini, M. Pizzuti, C. De Gregoris, V. Mettivier, A. Pastorini, G. Pizzolo, M. Vignetti, F. Mandelli and R. Foa. Absence of prognostic impact of CD13 and/or CD33 antigen expression in adult acute lymphoblastic leukemia. Results of the GIMEMA ALL 0496 trial. Haematologica :342-8 20. Zangrando, F. Intini, G. te Kronnie and G. Basso. Validation of NG2 antigen in identifying BP- ALL patients with MLL rearrangements using qualitative and quantitative flow cytometry: a prospective study. Leukemia : C. Medeiros, M. Othus, M. Fang, D. Roulston and F. R. Appelbaum. Prognostic impact of monosomal karyotype in young adult and elderly acute myeloid leukemia: the Southwest Oncology Group (SWOG) experience. Blood : Chapuy, R. Koch, U. Radunski, S. Corsham, N. Cheong, N. Inagaki, N. Ban, D. Wenzel, D. Reinhardt, A. Zapf, S. Schweyer, F. Kosari, W. Klapper, L. Truemper and G. G. Wulf. Intracellular ABC transporter A3 confers multidrug resistance in leukemia cells by lysosomal drug sequestration. Leukemia : Falini, K. Macijewski, T. Weiss, U. Bacher, S. Schnittger, W. Kern, A. Kohlmann, H.-U. Klein, M. Vignetti, A. Piciocchi, P. Fazi, M. P. Martelli, A. Vitale, S. Pileri, M. Miesner, A. Santucci, C. Haferlach, F. Mandelli and T. Haferlach. Multilineage dysplasia has no impact on biologic, clinicopathologic, and prognostic features of AML with mutated nucleophosmin (NPM1).[Erratum appears in Blood Aug 12;116(6):1017]. Blood : J. Lange, F. O. Smith, J. Feusner, D. R. Barnard, P. Dinndorf, S. Feig, N. A. Heerema, C. Arndt, R. J. Arceci, N. Seibel, M. Weiman, K. Dusenbery, K. Shannon, S. Luna-Fineman, R. B. Gerbing and T. A. Alonzo. Outcomes in CCG-2961, a children's oncology group phase 3 trial for untreated pediatric acute myeloid leukemia: a report from the children's oncology group. Blood : Jiao, C. F. Wu, Y. Liang, H. M. Chen, S. M. Xiong, B. Chen, J. Y. Shi, Y. Y. Wang, J. H. Wang, Y. Chen, J. M. Li, L. J. Gu, J. Y. Tang, Z. X. Shen, B. W. Gu, W. L. Zhao, Z. Chen and S. J. Chen. AML1-ETO9a is correlated with C-KIT overexpression/mutations and indicates poor disease outcome in t(8;21) acute myeloid leukemia-m2. Leukemia : Patel, L. Rai, G. Buck, S. M. Richards, Y. Mortuza, W. Mitchell, G. Gerrard, A. V. Moorman, V. Duke, A. V. Hoffbrand, A. K. Fielding, A. H. Goldstone and L. Foroni. Minimal residual disease is a significant predictor of treatment failure in non T-lineage adult acute lymphoblastic leukaemia: final results of the international trial UKALL XII/ECOG2993. Br J Haematol : van der Holt, D. A. Breems, H. Berna Beverloo, E. van den Berg, A. K. Burnett, P. Sonneveld and B. Lowenberg. Various distinctive cytogenetic abnormalities in patients with acute myeloid leukaemia aged 60 years and older express adverse prognostic value: results from a prospective clinical trial. British Journal of Haematology : A. Scrideli, J. G. Assumpcao, M. A. Ganazza, M. Araujo, S. R. Toledo, M. L. Lee, E. Delbuono, A. S. Petrilli, R. P. Queiroz, A. Biondi, M. B. Viana, J. A. Yunes, S. R. Brandalise and L. G. Tone. A simplified minimal residual disease polymerase chain reaction method at early treatment points can stratify children with acute lymphoblastic leukemia into good and poor outcome groups. Haematologica : A. Scrideli, M. A. A. Cortez, J. A. Yunes, R. G. d. P. Queiroz, E. T. Valera, J. F. da Mata, S. R. C. Toledo, P. Pavoni-Ferreira, M. L. d. M. Lee, A. S. Petrilli, S. R. Brandalise and L. G. Tone. mrna expression of matrix metalloproteinases (MMPs) 2 and 9 and tissue inhibitor of matrix metalloproteinases (TIMPs) 1 and 2 in childhood acute lymphoblastic leukemia: potential role of TIMP1 as an adverse prognostic factor. Leukemia Research :32-7 30. D. Baldus, J. Thibaut, N. Goekbuget, A. Stroux, C. Schlee, M. Mossner, T. Burmeister, S. Schwartz, C. D. Bloomfield, D. Hoelzer, E. Thiel and W.-K. Hofmann. Prognostic implications of NOTCH1 and FBXW7 mutations in adult acute T-lymphoblastic leukemia. Haematologica : D. Baldus, P. Martus, T. Burmeister, S. Schwartz, N. Gokbuget, C. D. Bloomfield, D. Hoelzer, E. Thiel and W. K. Hofmann. Low ERG and BAALC expression identifies a new subgroup of adult acute T-lymphoblastic leukemia with a highly favorable outcome. Journal of Clinical Oncology : G. Mullighan, J. Zhang, R. C. Harvey, J. R. Collins-Underwood, B. A. Schulman, L. A. Phillips, S. K. Tasian, M. L. Loh, X. Su, W. Liu, M. Devidas, S. R. Atlas, I. M. Chen, R. J. Clifford, D. S. Gerhard, W. L. Carroll, G. H. Reaman, M. Smith, J. R. Downing, S. P. Hunger and C. L. Willman. JAK mutations in high-risk childhood acute lymphoblastic leukemia. Proceedings of the National Academy of Sciences of the United States of America : Gregorj, M. R. Ricciardi, M. T. Petrucci, M. C. Scerpa, F. De Cave, P. Fazi, M. Vignetti, A. Vitale, M. Mancini, G. Cimino, S. Palmieri, F. Di Raimondo, G. Specchia, F. Fabbiano, N. Cantore, F. Mosna, A. Camera, M. Luppi, L. Annino, E. Miraglia, G. Fioritoni, F. Ronco, G. Meloni, F. Mandelli, M. Andreeff, M. Milella, R. Foa and A. Tafuri. ERK1/2 phosphorylation is an independent predictor of complete remission in newly diagnosed adult acute lymphoblastic leukemia. Blood : H. Pui, D. Pei, J. T. Sandlund, R. C. Ribeiro, J. E. Rubnitz, S. C. Raimondi, M. Onciu, D. Campana, L. E. Kun, S. Jeha, C. Cheng, S. C. Howard, M. L. Metzger, D. Bhojwani, J. R. Downing, W. E. Evans and M. V. Relling. Long-term results of St Jude Total Therapy Studies 11, 12, 13A, 13B, and 14 for childhood acute lymphoblastic leukemia. Leukemia : Haferlach, C. Mecucci, S. Schnittger, A. Kohlmann, M. Mancini, A. Cuneo, N. Testoni, G. Rege-Cambrin, A. Santucci, M. Vignetti, P. Fazi, M. P. Martelli, T. Haferlach and B. Falini. AML with mutated NPM1 carrying a normal or aberrant karyotype show overlapping biologic, pathologic, immunophenotypic, and prognostic features. Blood : J. Harrison, R. K. Hills, A. V. Moorman, D. J. Grimwade, I. Hann, D. K. Webb, K. Wheatley, S. S. de Graaf, E. van den Berg, A. K. Burnett and B. E. Gibson. Cytogenetics of childhood acute myeloid leukemia: United Kingdom Medical Research Council Treatment trials AML 10 and 12. J Clin Oncol : Kox, M. Zimmermann, M. Stanulla, S. Leible, M. Schrappe, W. D. Ludwig, R. Koehler, G. Tolle, O. R. Bandapalli, S. Breit, M. U. Muckenthaler and A. E. Kulozik. The favorable effect of activating NOTCH1 receptor mutations on long-term outcome in T-ALL patients treated on the ALL-BFM 2000 protocol can be separated from FBXW7 loss of function. Leukemia : Langer, M. D. Radmacher, A. S. Ruppert, S. P. Whitman, P. Paschka, K. Mrozek, C. D. Baldus, T. Vukosavljevic, C. G. Liu, M. E. Ross, B. L. Powell, A. de la Chapelle, J. E. Kolitz, R. A. Larson, G. Marcucci and C. D. Bloomfield. High BAALC expression associates with other molecular prognostic markers, poor outcome, and a distinct gene-expression signature in cytogenetically normal patients younger than 60 years with acute myeloid leukemia: a Cancer and Leukemia Group B (CALGB) study. Blood :5371-9 39. M. Santamaria, M. C. Chillon, R. Garcia-Sanz, C. Perez, M. D. Caballero, F. Ramos, A. G. de Coca, J. M. Alonso, P. Giraldo, T. Bernal, J. A. Queizan, J. N. Rodriguez, P. Fernandez-Abellan, A. Barez, M. J. Penarrubia, M. B. Vidriales, A. Balanzategui, M. E. Sarasquete, M. Alcoceba, J. Diaz-Mediavilla, J. F. San Miguel and M. Gonzalez. High FOXO3a expression is associated with a poorer prognosis in AML with normal cytogenetics. Leukemia Research : Muller-Tidow, H.-U. Klein, A. Hascher, F. Isken, L. Tickenbrock, N. Thoennissen, S. Agrawal- Singh, P. Tschanter, C. Disselhoff, Y. Wang, A. Becker, C. Thiede, G. Ehninger, U. zur Stadt, S. Koschmieder, M. Seidl, F. U. Muller, W. Schmitz, P. Schlenke, M. McClelland, W. E. Berdel, M. Dugas, H. Serve and L. Study Alliance. Profiling of histone H3 lysine 9 trimethylation levels predicts transcription factor activity and survival in acute myeloid leukemia. Blood : Oudot, M. F. Auclerc, V. Levy, R. Porcher, C. Piguet, Y. Perel, V. Gandemer, M. Debre, C. Vermylen, B. Pautard, C. Berger, C. Schmitt, T. Leblanc, J. M. Cayuela, G. Socie, G. Michel, G. Leverger and A. Baruchel. Prognostic factors for leukemic induction failure in children with acute lymphoblastic leukemia and outcome after salvage therapy: the FRALLE 93 study. J Clin Oncol : Rollig, C. Thiede, M. Gramatzki, W. Aulitzky, H. Bodenstein, M. Bornhauser, U. Platzbecker, R. Stuhlmann, U. Schuler, S. Soucek, M. Kramer, B. Mohr, U. Oelschlaegel, F. Stolzel, M. von Bonin, M. Wermke, H. Wandt, G. Ehninger and M. Schaich. A novel prognostic model in elderly patients with acute myeloid leukemia: results of 909 patients entered into the prospective AML96 trial. Blood : Santamaria, M. C. Chillon, R. Garcia-Sanz, A. Balanzategui, M. E. Sarasquete, M. Alcoceba, F. Ramos, T. Bernal, J. A. Queizan, M. J. Penarrubia, P. Giraldo, J. F. San Miguel and M. Gonzalez. The relevance of preferentially expressed antigen of melanoma (PRAME) as a marker of disease activity and prognosis in acute promyelocytic leukemia. Haematologica : Santamaria, M. C. Chillon, R. Garcia-Sanz, C. Perez, M. D. Caballero, M. V. Mateos, F. Ramos, A. G. de Coca, J. M. Alonso, P. Giraldo, T. Bernal, J. A. Queizan, J. N. Rodriguez, N. Puig, A. Balanzategui, M. E. Sarasquete, M. Alcoceba, J. Diaz-Mediavilla, J. San Miguel and M. Gonzalez. BAALC is an important predictor of refractoriness to chemotherapy and poor survival in intermediate-risk acute myeloid leukemia (AML). Ann Hematol : A. Breems, W. L. J. Van Putten, G. E. De Greef, S. L. Van Zelderen-Bhola, K. B. J. Gerssen- Schoorl, C. H. M. Mellink, A. Nieuwint, M. Jotterand, A. Hagemeijer, H. B. Beverloo and B. Lowenberg. Monosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotype. Journal of Clinical Oncology : Barbaric, T. A. Alonzo, R. B. Gerbing, S. Meshinchi, N. A. Heerema, D. R. Barnard, B. J. Lange, W. G. Woods, R. J. Arceci and F. O. Smith. Minimally differentiated acute myeloid leukemia (FAB AML-M0) is associated with an adverse outcome in children: a report from the Children's Oncology Group, studies CCG-2891 and CCG Blood : Grimwade, R. K. Hills, A. V. Moorman, H. Walker, S. Chatters, A. H. Goldstone, K. Wheatley, C. J. Harrison and A. K. Burnett. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood : I. Marks, E. M. Paietta, A. V. Moorman, S. M. Richards, G. Buck, G. DeWald, A. Ferrando, A. K. Fielding, A. H. Goldstone, R. P. Ketterling, M. R. Litzow, S. M. Luger, A. K. McMillan, M. R. Mansour, J. M. Rowe, M. S. Tallman and H. M. Lazarus. T-cell acute lymphoblastic leukemia in adults: clinical features, immunophenotype, cytogenetics, and outcome from the large randomized prospective trial (UKALL XII/ECOG 2993). Blood : J. P. M. Stumpel, P. Schneider, E. H. J. van Roon, J. M. Boer, P. de Lorenzo, M. G. Valsecchi, R. X. de Menezes, R. Pieters and R. W. Stam. Specific promoter methylation identifies different subgroups of MLL-rearranged infant acute lymphoblastic leukemia, influences clinical outcome, and provides therapeutic options. Blood : L. Johnston, T. A. Alonzo, R. B. Gerbing, B. J. Lange and W. G. Woods. The presence of central nervous system disease at diagnosis in pediatric acute myeloid leukemia does not affect survival: a Children's Oncology Group study. Pediatric Blood & Cancer : Voskova, S. Schnittger, C. Schoch, T. Haferlach and W. Kern. Use of five-color staining improves the sensitivity of multiparameter flow cytomeric assessment of minimal residual disease in patients with acute myeloid leukemia. Leuk Lymphoma : Clappier, S. Collette, N. Grardel, S. Girard, L. Suarez, G. Brunie, S. Kaltenbach, K. Yakouben, F. Mazingue, A. Robert, P. Boutard, D. Plantaz, P. Rohrlich, P. van Vlierberghe, C. Preudhomme, J. Otten, F. Speleman, N. Dastugue, S. Suciu, Y. Benoit, Y. Bertrand and H. Cave. NOTCH1 and FBXW7 mutations have a favorable impact on early response to treatment, but not on outcome, in children with T-cell acute lymphoblastic leukemia (T-ALL) treated on EORTC trials and Leukemia : Csinady, V. H. J. van der Velden, R. Joas, S. Fischer, J. F. de Vries, H. B. Beverloo, M. Konig, U. Potschger, J. J. M. van Dongen, G. Mann, O. A. Haas and E. R. Panzer-Grumayer. Chromosome 14 copy number-dependent IGH gene rearrangement patterns in high hyperdiploid childhood B-cell precursor ALL: implications for leukemia biology and minimal residual disease analysis. Leukemia : Flex, V. Petrangeli, L. Stella, S. Chiaretti, T. Hornakova, L. Knoops, C. Ariola, V. Fodale, E. Clappier, F. Paoloni, S. Martinelli, A. Fragale, M. Sanchez, S. Tavolaro, M. Messina, G. Cazzaniga, A. Camera, G. Pizzolo, A. Tornesello, M. Vignetti, A. Battistini, H. Cave, B. D. Gelb, J.-C. Renauld, A. Biondi, S. N. Constantinescu, R. Foa and M. Tartaglia. Somatically acquired JAK1 mutations in adult acute lymphoblastic leukemia. Journal of Experimental Medicine : Forestier, M. Heyman, M. K. Andersen, K. Autio, E. Blennow, G. Borgstrom, I. Golovleva, S. Heim, K. Heinonen, R. Hovland, J. H. Johannsson, G. Kerndrup, A. Nordgren, R. Rosenquist, B. Swolin and B. Johansson. Outcome of ETV6/RUNX1-positive childhood acute lymphoblastic leukaemia in the NOPHO-ALL-1992 protocol: frequent late relapses but good overall survival. Br J Haematol : Taskesen, L. Bullinger, A. Corbacioglu, M. A. Sanders, C. A. Erpelinck, B. J. Wouters, S. C. van der Poel-van de Luytgaarde, F. Damm, J. Krauter, A. Ganser, R. F. Schlenk, B. Lowenberg, R. Delwel, H. Dohner, P. J. Valk and K.
Similar documents
View more...
Related Search
We Need Your Support
Thank you for visiting our website and your interest in our free products and services. We are nonprofit website to share and download documents. To the running of this website, we need your help to support us.

Thanks to everyone for your continued support.

No, Thanks